Explore how revolutionary weight-loss medications like Ozempic are transforming lives while raising crucial questions about accessibility, side effects, and long-term sustainability in the Indian context.
Discover the hidden connection between rapid weight fluctuations and kidney damage. Learn about risk factors, prevention tips, and when to seek medical help.
Discover the surprising medical conditions that could be causing your breathlessness during simple walks. Learn when to seek medical attention for this common symptom.
Indian stock markets extend losses amid global uncertainty. Sensex tanks 465 points, Nifty slips below 25,750. Discover the 10 key factors driving this market selloff and what investors should watch.
Bengaluru medical experts sound alarm on diabetes drugs being misused for weight loss, highlighting dangerous side effects and long-term health risks.
Eli Lilly is developing Orforglipron oral pills for weight loss and type 2 diabetes that could replace injections, making treatment more accessible and convenient for millions.
Pharmaceutical giant Eli Lilly raises full-year profit forecast as demand skyrockets for revolutionary weight-loss treatment Zepbound, sending shares climbing 7%.
Acanthosis Nigricans, the dark skin patch on children's necks, is emerging as a visible warning sign of India's growing childhood obesity crisis and early diabetes risk.
Get the latest grey market premium updates for Orkla India IPO, Studds Accessories IPO, and Lenskart IPO. Discover which stocks are generating maximum investor buzz in today's primary market.
Discover how revolutionary GLP-1 medications including Ozempic, Wegovy, and Mounjaro are transforming America's battle against obesity, offering new hope for sustainable weight loss.
Former Novo Nordisk CEO Lars Fruergaard Jørgensen reveals why revolutionary weight-loss drugs need comprehensive healthcare strategies to tackle obesity effectively. Discover the missing pieces in the fight against this global epidemic.
India faces a dual health crisis as obesity rates surge alongside undernutrition, creating a massive economic burden that threatens national productivity and healthcare systems.
Discover how excess weight secretly damages your skin elasticity, causes hair thinning, and triggers premature aging. Expert insights on the surprising connection between weight and beauty.
Groundbreaking research shows popular weight-loss drug semaglutide significantly reduces heart disease risk, offering dual benefits for patients struggling with obesity and cardiovascular health.
Discover the surprising daily routines that are sabotaging your weight loss goals. From sleep patterns to eating speed, learn how to break these obesity-triggering habits.
Groundbreaking research from Pune reveals diabetes drug semaglutide significantly reduces cardiovascular risks in non-diabetic patients, offering dual benefits for weight and heart health.
In a groundbreaking move, Eli Lilly partners with Cipla to dramatically expand availability of innovative weight loss therapies across India, addressing the growing obesity crisis.
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Pharma giant Eli Lilly collaborates with Indian partner Cipla to introduce groundbreaking obesity and diabetes treatments Mounjaro and Yurpeak in the Indian market, expanding access to innovative weight management solutions.
Major shakeup in Indian derivatives market as SEBI mandates uniform 4:00 PM expiry for index options on both BSE and NSE exchanges. Discover how this strategic shift will impact market dynamics, trading volumes, and investor opportunities.
Get exclusive insights from market veteran Raja Venkatraman as he shares his top stock recommendations for October. Discover which sectors and specific companies are poised for significant growth in the current market scenario.
New medical research reveals shocking connection between modern lifestyle habits and rising cancer rates among adults under 50. Learn how obesity, sedentary routines, and dietary choices are creating a health crisis.
Indian pharmaceutical leader Biocon Biologics partners with Civica to disrupt US insulin market with affordable alternatives, while also eyeing anti-obesity therapy opportunities.
Groundbreaking research reveals a disturbing surge in obesity-related cancers affecting Indians across all age groups. Learn which cancers show the strongest connection and what experts recommend for prevention.
As Samvat 2082 begins, Indian markets show strong bullish signals with expected double-digit returns. However, global uncertainties and domestic challenges could test investor resilience. Discover the key opportunities and risks shaping your portfolio.
Incred Equities turns overwhelmingly bullish on Indian markets, projecting Nifty 50 to reach 28,433 by December 2026. Discover the key drivers behind this optimistic forecast.
While Indian markets celebrate record highs, alarming signals beneath the surface suggest potential turbulence ahead. Discover the hidden risks that could derail the bull run.
Get ready for a volatile week ahead! Discover the key factors including Q4 earnings, global cues, FII activity, and technical levels that will shape market movement. Essential reading for Indian stock market investors.
Discover why some obese individuals remain metabolically healthy while others develop serious conditions. Learn about fat distribution, lifestyle factors, and prevention strategies from medical experts.
Discover why being thin doesn't mean you're healthy. Learn about 'skinny fat' - the silent threat increasing heart disease risk among Indians with normal BMI.